Immunic (IMUX) Competitors $0.90 +0.06 (+7.53%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.02 (-2.10%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. RNAC, NGNE, GOSS, OCGN, FHTX, TKNO, ADCT, PVLA, TSVT, and CRVSShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Cartesian Therapeutics (RNAC), Neurogene (NGNE), Gossamer Bio (GOSS), Ocugen (OCGN), Foghorn Therapeutics (FHTX), Alpha Teknova (TKNO), ADC Therapeutics (ADCT), Palvella Therapeutics (PVLA), 2seventy bio (TSVT), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Its Competitors Cartesian Therapeutics Neurogene Gossamer Bio Ocugen Foghorn Therapeutics Alpha Teknova ADC Therapeutics Palvella Therapeutics 2seventy bio Corvus Pharmaceuticals Cartesian Therapeutics (NASDAQ:RNAC) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership. Which has more volatility and risk, RNAC or IMUX? Cartesian Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Do analysts rate RNAC or IMUX? Cartesian Therapeutics presently has a consensus target price of $40.00, indicating a potential upside of 201.43%. Immunic has a consensus target price of $7.50, indicating a potential upside of 737.24%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Immunic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has preferable earnings & valuation, RNAC or IMUX? Cartesian Therapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$34.17M10.08-$77.42M-$52.83-0.25ImmunicN/AN/A-$100.51M-$1.23-0.73 Does the media prefer RNAC or IMUX? In the previous week, Cartesian Therapeutics had 6 more articles in the media than Immunic. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Immunic. Cartesian Therapeutics' average media sentiment score of 0.95 beat Immunic's score of 0.47 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RNAC or IMUX more profitable? Cartesian Therapeutics' return on equity of 0.00% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -7.01% Immunic N/A -326.95%-181.34% Do insiders and institutionals believe in RNAC or IMUX? 86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 4.6% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryCartesian Therapeutics beats Immunic on 9 of the 14 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.83M$2.93B$5.57B$9.32BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.7320.5028.6419.75Price / SalesN/A267.15432.34182.50Price / CashN/A43.1536.0257.96Price / Book4.487.768.235.67Net Income-$100.51M-$55.11M$3.24B$257.98M7 Day Performance11.17%1.03%0.05%0.56%1 Month Performance9.18%8.54%5.65%8.88%1 Year Performance-39.47%-2.26%26.57%14.24% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.4802 of 5 stars$0.90+7.5%$7.50+737.2%-38.7%$85.83MN/A-0.7370RNACCartesian Therapeutics2.2256 of 5 stars$10.98-2.1%$40.67+270.5%-24.2%$284.80M$38.91M-0.2164NGNENeurogene3.219 of 5 stars$19.54-2.7%$46.17+136.3%-53.3%$279.28M$930K-4.5090GOSSGossamer Bio3.7713 of 5 stars$1.22-2.0%$7.33+503.6%+22.9%$276.17M$114.70M-5.28180News CoverageAnalyst ForecastOCGNOcugen1.3749 of 5 stars$0.96-0.2%$6.00+528.3%-44.0%$274.51M$4.05M-4.9580FHTXFoghorn Therapeutics2.0876 of 5 stars$4.84-5.6%$12.13+150.4%-7.2%$268.90M$23.50M-3.55120Positive NewsTKNOAlpha Teknova2.0323 of 5 stars$5.02-3.6%$8.50+69.3%+243.8%$268.54M$37.74M-10.47240Positive NewsADCTADC Therapeutics1.5381 of 5 stars$2.71-5.1%$7.75+186.5%-19.1%$268.28M$75.82M-1.87310PVLAPalvella Therapeutics2.5116 of 5 stars$24.14+0.1%$46.29+91.7%N/A$266.99M$42.81M-2.00N/APositive NewsTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440CRVSCorvus Pharmaceuticals2.8334 of 5 stars$3.89-1.5%$15.00+285.6%+108.5%$264.16MN/A-3.9530Positive News Related Companies and Tools Related Companies Cartesian Therapeutics Alternatives Neurogene Alternatives Gossamer Bio Alternatives Ocugen Alternatives Foghorn Therapeutics Alternatives Alpha Teknova Alternatives ADC Therapeutics Alternatives Palvella Therapeutics Alternatives 2seventy bio Alternatives Corvus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMUX Stock Alerts